Early relapse of follicular lymphoma may increase risk of death
the ONA take:
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients, according to a new study published online ahead of print in the Journal of Clinical Oncology.
Researchers at the University of Rochester in New York and colleagues analyzed data from the National LymphoCare Study in order to evaluate whether patients with follicular lymphoma who experience progression of disease within 2 years of initial R-CHOP therapy have an increased risk of death.
Results showed that the 5-year overall survival was 50% for those who experienced early progression of disease compared with 90% among those who did not.
"Through research we have confirmed that all relapsed patients are not equal, and therefore should not be approached the same at diagnosis nor at the time of relapse in terms of therapies," Carla Casulo, MD, oncologist and assistant professor of Medicine at the University of Rochester said.
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|